SynthesisRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2023
A systematic review on extensively drug-resistant tuberculosis from 2009 to 2020: special emphases on treatment outcomes.
Synthesis in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- A scoping review of interventions in childhood tuberculosis prevention and treatment.Public health in practice (Oxford, England) · 2026Review
- Success rates of DR-TB patients and associated factors in Tanzania: a six-year cohort study.BMC infectious diseases · 2026Article
- Factors associated with unsuccessful treatment outcomes among drug-resistant tuberculosis patients in Loreto, Peru, 2015-2023: A retrospective cohort study.PLOS global public health · 2026Article
- High Rates of Mortality During Drug-Resistant Tuberculosis Treatment Among Individuals With Diabetes Mellitus and Low Body Mass Index.Open forum infectious diseases · 2025Article
- Effects of Kanamycin on Hearing and Vestibular Function in Multidrug-Resistant Tuberculosis Patients.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Advancing Vaccinology Capacity: Education and Efforts in Vaccine Development and Manufacturing across Africa.Vaccines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveExtensively drug-resistant tuberculosis (XDR-TB) has raised a great threat to human health globally, especially in developing countries. The objective of the present study is to collate and contrast the proportions of treatment outcome in the previously published XDR-TB articles.
methodsBy considering inclusion criteria and search engines, a total of 22 articles were enrolled.
resultsOur findings revealed that the overall favorable treatment outcome was 24.04%. From the cohort of enrolled studies 19.76% (397) and 43.35% (871) patients were cured and died respectively. In 90.9% of enrolled articles, the investigators performed drug-susceptibility testing at the baseline. The overall treatment outcome was improved by the use of new drugs (linezolid, bedaquiline, ciprofloxacin, clofazimine) in the treatment regimen of XDR-TB showing linezolid and bedaquiline better results i.e. 59.44 and 78.88%, respectively. Moreover, use of antiretroviral treatment in XDR-TB patients with HIV infection have not shown any significant difference in the treatment outcome.
conclusionsXDR-TB treatment success can be achieved by implying standardized definitions, upgraded diagnostic procedures, and novel drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.